The BioLabs LA BioMed innovation center will accommodate up to 30 new companies and is uniquely designed to help startups go further and faster on limited capital investment.
The Los Angeles Biomedical Research Institute (LA BioMed) and BioLabs, a network of shared lab facilities designed to manage all aspects of operations for high-potential, early-stage life science companies, today announced the Spring 2019 opening of a new Los Angeles incubator.
Located at a 78,000-square foot, is an $65 million research building at LA BioMed next to the Harbor-UCLA Medical Center in Torrance.
BioLabs LA BioMed is currently accepting applications for bioscience startups for the Spring 2019 term. An 18,000-square foot facility that offers users access to state-of-the-art lab and office facilities, more than $1 million in shared equipment, and world-class programming and events from world-class programming and events from LA BioMed’s distinguished roster of more than 400 researchers, several of whom have launched their own startups; and premium co-working space that is designed to scale to a company’s growth, whether a single lab bench or a suite of offices.
As with all BioLabs sites, the Los Angeles innovation center is designed by a team of scientists and entrepreneurs with decades of experience in business formation and startup success. The innovation centers offer flexible, fully-equipped and permitted shared lab and office spaces with inspired designs that foster interaction and collaboration. The centers also provide concierge service as well as technical and administrative support. BioLabs LA BioMed is part of BioLabs’ growing network of facilities, which includes locations in San Diego, Calif., Raleigh-Durham, N.C., Princeton, N.J., Boston and Cambridge, Mass.; the San Francisco Bay Area, Calif.; Philadelphia, Pa. and New York, N.Y.
“LA BioMed has been able to attract a roster of highly innovative companies, who will help make BioLabs LA BioMed the premier space for a biotech startup to launch, grow, and create new job opportunities,” said Johannes Fruehauf, M.D. Ph.D., President and CEO, BioLabs.